Clinical effect of breviscapine combined with nerve growth factor in ischemic optic neuropathy / 中国生化药物杂志

ABSTRACT

Objective To investigate clinical effect of breviscapine combined with nerve growth factor in treatment of ischemic optic neuropathy . Methods 80 patients with ischemic optic neuropathy from March 2014 to March 2016 in our hospital were selected and divided into the control group and observation group, 40 cases in each group.The control group was treated with nerve growth factor, hip injection 30ug, one times a day, while the observation group was treated with breviscapine combined with nerve growth factor, 80 mg breviscapine added to 500 mL glucose intravenous infusion, one times a day.Then the changes of visual acuity, visual field loss difference (LV), the average damage of vision (MD), the average vision light sensitivity ( MS ) , adverse reactions, curative effect were compared between two groups.Results After treatment, the total effective rate in the observation group was significantly higher than the control group, the difference was statistically significant (P<0.05), the visual acuity of the observation group was significantly higher than that of the control group, the difference was statistically significant (P<0.05), LV, MD was significantly lower than the control group, the difference was statistically significant (P<0.05), MS was significantly higher than the control group, the difference was statistically significant (P<0.05).There was no difference in adverse reactions between the two groups.Conclusion Breviscapine combined with nerve growth factor in the treatment of ischemic optic neuropathy can improve nerve function of patients , improve the therapeutic effect.